BiochemProbe — Life Science Research Reagents

NT-0796 free base · Synonyms: NT 0796 · NT0796

NT-0796 is a selective and CNS-penetrant NLRP3 inflammasome inhibitor.

For research use only. Not for human or veterinary use.

Purity >98% Stock Inquire

NT-0796 structure

CAS No.: 2272917-13-0

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
10 mg USD 565.00 BP-02258-10mg In stock Get quote
25 mg USD 1,085.00 BP-02258-25mg In stock Get quote
50 mg USD 1,685.00 BP-02258-50mg In stock Get quote
100 mg USD 2,084.00 BP-02258-100mg In stock Get quote
200 mg Inquire BP-02258-200mg In stock Inquire
1 g Inquire BP-02258-1g In stock Inquire

Need another size or custom synthesis? Request a quote.

Description

NT-0796 is a selective and CNS-penetrant NLRP3 inflammasome inhibitor with an IC50 of 0.32 nM in PBMC assay.

Biological activity

NT-0796 is a selective and CNS-penetrant NLRP3 inflammasome inhibitor with an IC50 of 0.32 nM in PBMC assay. NT-0796 is an isopropyl ester that undergoes intracellular conversion to NDT-19795, the carboxylic acid active species. NT-0796 has the potential for neuroinflammatory diseases research.

Identifiers

SMILES
O=C(O[C@H](CC1=NC=CC=N1)C(OC(C)C)=O)NC2=C3C(CCC3)=CC4=C2CCC4
InChIKey
UMUQEMHROZVOTF-LJQANCHMSA-N

Specifications

MW (average)
409.4782
Formula
C23H27N3O4
CAS No.
2272917-13-0
Physical state
Solid
Color
White to off-white
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder   -20°C, 3 years , 4°C, 2 years ; In solvent    -20°C, 1 month

Solubility

Soluble in DMSO

In vitro
DMSO : 100 mg/mL

References

[1]. David Harrison, et al. Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders. J Med Chem. 2023 Oct 24.
[2]. Thornton P, et al. Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796. J Pharmacol Exp Ther. 2024 Feb 15;388(3):813-826.
[3]. Smolak P, et al. Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency. J Pharmacol Exp Ther. 2024 Feb 15;388(3):798-812.
[4]. Doedens JR, et al. The ester-containing prodrug NT-0796 enhances delivery of the NLRP3 inflammasome inhibitor NDT-19795 to monocytic cells expressing carboxylesterase-1. Biochem Pharmacol. 2024 Sep;227:116455.

Same research area

Search Neurological Disease